AQS Aequus Pharmaceuticals Inc
- 0.040
- +0.020+100.00%
Aequus Pharmaceuticals Inc News
Aequus Reports Q1 Financials and ZIMED PF Launch
Aequus Pharmaceuticals Inc. reports a reduced operating loss and a decline in overall revenue in Q1 2024, largely due to halting Evolve product sales, despite the launch of the new ZIMED® PF ophthalmic solution. The company has seen a decrease in expenses and is implementing marketing strategies to boost ZIMED® PF demand after its initial adoption met expectations. Meanwhile, research and development costs dropped to zero with the completed approval process for ZIMED® PF.
Aequus Says Zimed PF Now Available in Canada
Aequus Pharmaceuticals Inc. (AQS.V) on Thursday announced the launch of Zimed PF, the first preservative-free multi-dose Bimatoprost for glaucoma patients in Canada. "This marks a new growth phase for
Aequus Pharmaceuticals Announces Zimed PF Website Launch
Aequus Pharmaceuticals Inc. (AQS.V), a specialty pharmaceutical company, has launched its education website for patients and professionals. With a focus on elevated, interocular pressure, Glaucoma and
Aequus Pharmaceuticals Pauses Sales Of Evolve Intensive Eyedrops, Gel in Canada
Aequus Pharmaceuticals Inc. (AQS.V) said Friday that it has paused sales of its Evolve Intensive eyedrop and Intensive gel products in Canada. Aequus said product manufacturer Medicom Healthcare (UK)
Aequus Pharmaceuticals Inc. (CVE:AQS) Director Buys C$11,400.00 in Stock
Aequus Pharmaceuticals Inc. (CVE:AQS – Get Rating) Director Doug Janzen acquired 285,000 shares of the business's stock in a transaction on Wednesday, November 30th. The shares were purchased at an a
Transdermal Drug Delivery Pipeline Report 2022 - ResearchAndMarkets.com
The "Transdermal Drug Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
Press Release for Early Warning Report Regarding Aequus Pharmaceuticals Inc.
VANCOUVER, British Columbia, July 23, 2022 (GLOBE NEWSWIRE) -- Doug Janzen, of 2820 – 200 Granville St., Vancouver, BC, V6C 1S4, today announced that on Tuesday, July 19, 2022, he acquired ownership (the "Acquisition") of 100,000 common shares ("Comm
